Sinoway Industrial Co., Ltd.

Pitavastatin Calcium Intermediates 147511-70-4/147489-06-3 Pitavastatin Calcium Intermediates 147511-70-4/147489-06-3

Pitavastatin Calcium Intermediates 147511-70-4/147489-06-3
Related Products
  • Mupirocin 12650-69-0

    Details of MupirocinOther Names: mupirocinMF: C26H44O9Place of Origin: Fujian, China (Mainland)Type: Auxiliaries and Other Medicinal Chemicals, Immune Function AgentsGrade Standard: Medicine GradeBran...

  • Atracurium Besylate 64228-81-5

    Basic information of Atracurium besylate:NameAtracurium besylateAliasCAS NO.64228-81-5 Molecular FormulaC65H82N2O18S2Molecular Weight1243.48Quality StandardCurrent USPPackage Size2kg or 3kg/tin/carton...

  • Ceftiofur Sodium 104010-37-9

    Basic information of Ceftiofur sodium:NameCeftiofur sodiumCAS :104010-37-9Molecular FormulaC19H16N5NaO7S3Molecular Weight545.54Quality StandardPackage SizeFor small quantity:Double plastic bag inside ...

Basic Information of Pitavastatin Calcium Intermediates 147511-70-4/147489-06-3

  • CAS No of key intermediates.: 147511-70-4
  • 147489-06-3
  • Other Names: Pitavastatin Calcium
  • MF: (C25H23FNO4)2.Ca
  • Molecular Weight 880.98
  • Purity: pitavastatin calcium china 99%
  • Appearance: White crystal powder
  • tandard: in-house standard
  • grade: medical grade
  • Specifications: DMF available

Usage of Pitavastatin Calcium Intermediates 147511-70-4/147489-06-3

  • Intermediates of Pitavastatin Calcium.
  • Pitavastatin Calcium is used For the treatment of high cholesterol, familial hypercholesterolemia.

Note:

  1. before using this medicine should be fully checked, the diagnosis is high cholesterol or familial hypercholesterolemia, can use.
  2. Familial hypercholesterolemia in patients with homomorphone lack of treatment experience, clinically determined to be invalid after treatment, the drug can be used as an adjunct to LDL non-drug therapy.

Caution (the following patients should be careful to use this drug may cause rhabdomyolysis and other adverse reactions)

  1. patients with liver disease or those with liver disorders, alcoholism (because the drug is mostly distributed to the liver)
  2. kidney disease patients or those who have kidney disease
  3. Patients taking phenoxyacetic or niacin
  4. Patients with hypothyroidism, hereditary muscular dysfunction, or who have had this history
  5. The elderly
Important note
  1. for high cholesterol patients should still be the first to take diet therapy, and pay attention to exercise therapy
  2. start of medication to 12 weeks, at least for a liver function test, after 12 weeks, you can do a semi-annual inspection 1
  3. During the medication, blood lipids should be regularly checked, if there is no effect in the prescribed treatment, should be discontinued

MORE_DETAIL Pitavastatin Calcium Intermediates 147511-70-4/147489-06-3

Basic Information of Pitavastatin Calcium Intermediates 147511-70-4/147489-06-3

  • CAS No of key intermediates.: 147511-70-4
  • 147489-06-3
  • Other Names: Pitavastatin Calcium
  • MF: (C25H23FNO4)2.Ca
  • Molecular Weight 880.98
  • Purity: pitavastatin calcium china 99%
  • Appearance: White crystal powder
  • tandard: in-house standard
  • grade: medical grade
  • Specifications: DMF available

Usage of Pitavastatin Calcium Intermediates 147511-70-4/147489-06-3

  • Intermediates of Pitavastatin Calcium.
  • Pitavastatin Calcium is used For the treatment of high cholesterol, familial hypercholesterolemia.

Note:

  1. before using this medicine should be fully checked, the diagnosis is high cholesterol or familial hypercholesterolemia, can use.
  2. Familial hypercholesterolemia in patients with homomorphone lack of treatment experience, clinically determined to be invalid after treatment, the drug can be used as an adjunct to LDL non-drug therapy.

Caution (the following patients should be careful to use this drug may cause rhabdomyolysis and other adverse reactions)

  1. patients with liver disease or those with liver disorders, alcoholism (because the drug is mostly distributed to the liver)
  2. kidney disease patients or those who have kidney disease
  3. Patients taking phenoxyacetic or niacin
  4. Patients with hypothyroidism, hereditary muscular dysfunction, or who have had this history
  5. The elderly
Important note
  1. for high cholesterol patients should still be the first to take diet therapy, and pay attention to exercise therapy
  2. start of medication to 12 weeks, at least for a liver function test, after 12 weeks, you can do a semi-annual inspection 1
  3. During the medication, blood lipids should be regularly checked, if there is no effect in the prescribed treatment, should be discontinued
Related Articles
Leave a Message Email Us

we will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//